Managing Partner
Dr. Alon Lazarus joined Arkin Bio in 2013 as a Managing Partner, leading investments in pharmaceutical companies from early stages through public offerings in the U.S. He served on the board of several of Arkin's pharmaceutical companies, including Bluejay Therapeutics (acquired by Mirum), HI-Bio (acquired by Biogen) Enact Bio, Auron Therapeutics, Modal Therapeutics, and Werewolf Therapeutics (NASDAQ: HOWL). Earlier in his career, he worked in the healthcare business development department of Yissum, the R&D arm of the Hebrew University of Jerusalem.
Throughout his career, Alon contributed meaningfully to the biotechnology industry and the broader healthcare field. His commitment to science and his drive to advance novel therapies left a lasting mark on the companies he supported and the people he worked with. He is deeply missed.
Let’s get in touch!
